Investing.com — Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN )，一家市值389万美元的微型制药公司，在其总裁、CEO和董事长Pankaj Mohan于2025年3月31日去世后宣布了重大领导层变动。根据 InvestingPro ...

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today ...

Sonnet BioTherapeutics Holdings, Inc. PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company ...

PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), an oncology-focused biotech company with a market capitalization of $4.11 million, has announced the appointment of Raghu Rao as ...

Chatgpt、claude等生成式人工智能平台的崛起，让更多人意识到了“AI的时代已经到来”，而国内deepseek模型中的“深度思考”模式却让全世界为之震撼。

The Claude 3.7 Sonnet model, developed by Anthropic, is making significant strides in the realm of AI automation. By integrating seamlessly with the Vector Shift platform, it assists the creation ...

Sonnet BioTherapeutics (SONN) announced positive findings from the first safety review of the expansion cohort in its Phase 1 SB101 clinical ...

Claude 3.7 Sonnet is accessible across various platforms ... set at $3 per million input tokens and $15 per million output ...